Texas Center for Drug Development | Houston, TX
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins). Treatment of MOH usually involves reducing the dose of or discontinuing acute medications.
Eptinezumab is a medication used for the preventive treatment of migraine in adults. The main goals of this trial are to learn whether eptinezumab helps reduce the number of days with migraine, the number of days with headache, and acute medication use in adults who have migraine and MOH.
Full description
The total study duration from screening visit to safety follow-up visit is approximately 36 weeks and includes a screening period (4 weeks), a placebo-controlled period (12 weeks), an open-label period (12 weeks), and a safety follow-up period (8 weeks).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Other inclusion and exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
570 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Email contact via H. Lundbeck A/S
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal